Hsa-miR-181a-5p, hsa-miR-182-5p, and hsa-miR-26a-5p as potential biomarkers for BCR-ABL1 among adult chronic myeloid leukemia treated with tyrosine kinase inhibitors at the molecular response

BACKGROUND: Tyrosine kinase inhibitors (TKIs) as first-line therapy for Chronic Myeloid Leukemia (CML) show a high success rate. However, a low number of patients with long-term treatment-free remission (TFR) were observed. Molecular relapse after imatinib discontinuation occurred at 50% at 24 month...

Descripción completa

Detalles Bibliográficos
Autores principales: Mohd Yacob, Aliza, Muhamad, Nor Asiah, Chang, Kian Meng, Akmal Hisham, Hamidah, Mat Yusoff, Yuslina, Ibrahim, Latifah
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8962036/
https://www.ncbi.nlm.nih.gov/pubmed/35346116
http://dx.doi.org/10.1186/s12885-022-09396-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8962036/
https://www.ncbi.nlm.nih.gov/pubmed/35346116
http://dx.doi.org/10.1186/s12885-022-09396-5

Ejemplares similares